Dual targeting of the thioredoxin and glutathione systems in cancer and HIV

Journal of Clinical Investigation

Volumn 126, Issue 5, 2016, Pages 1630-1639

  Benhar, Moran ^a   Shytaj, Iart Luca ^b   Stamler, Jonathan S ^c   Savarino, Andrea ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ASCORBIC ACID; AURANOFIN; BUTHIONINE SULFOXIMINE; CAROTENOID; DEOXYGLUCOSE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; GLUTATHIONE; MELPHALAN; NITRIC OXIDE; NITRIC OXIDE DONOR; RETINOIC ACID; RETINOL; SELENIUM; THIOREDOXIN; VINCRISTINE; ZINC;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BREAST TUMOR; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOMA; NEOPLASM; NEUROBLASTOMA; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; VIRUS IMMUNITY; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE; NEOPLASMS; PATHOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; GLUTATHIONE; HIV-1; HUMANS; MICE; NEOPLASMS; OXIDATION-REDUCTION; THIOREDOXINS;

EID: 84988515291     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85339     Document Type: Review

References (135)

1. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6(2):150-166.
2. Janssen-Heininger YM, et al. Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic Biol Med. 2008;45(1):1-17.
3. Go YM, Jones DP. The redox proteome. J Biol Chem. 2013;288(37):26512-26520.
4. Lillig CH, Holmgren A. Thioredoxin and related molecules - from biology to health and disease. Antioxid Redox Signal. 2007;9(1):25-47.
5. Ghezzi P. Protein glutathionylation in health and disease. Biochim Biophys Acta. 2013;1830(5):3165-3172.
6. Zhang H, Forman HJ. Glutathione synthesis and its role in redox signaling. Semin Cell Dev Biol. 2012;23(7):722-728.
7. Benhar M, Forrester MT, Stamler JS. Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol. 2009;10(10):721-732.
8. Mandal PK, et al. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res. 2010;70(22):9505-9514.
9. Prigge JR, et al. Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1. Free Radic Biol Med. 2012;52(4):803-810.
10. Levring TB, et al. Human CD4+ T cells require exogenous cystine for glutathione and DNA synthesis. Oncotarget. 2015;6(26):21853-21864.
11. Du Y, Zhang H, Lu J, Holmgren A. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. J Biol Chem. 2012;287(45):38210-38219.
12. Jones DP, Go YM. Redox compartmentalization and cellular stress. Diabetes Obes Metab. 2010;12(suppl 2):116-125.
13. Go YM, et al. Selective targeting of the cysteine proteome by thioredoxin and glutathione redox systems. Mol Cell Proteomics. 2013;12(11):3285-3296.
14. Pader I, et al. Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase. Proc Natl Acad Sci U S A. 2014;111(19):6964-6969.
15. Benhar M. Nitric oxide and the thioredoxin system: A complex interplay in redox regulation. Biochim Biophys Acta. 2015;1850(12):2476-2484.
16. Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med. 2014;66:75-87.
17. Buettner GR, Wagner BA, Rodgers VG. Quantitative redox biology: an approach to understand the role of reactive species in defining the cellular redox environment. Cell Biochem Biophys. 2013;67(2):477-483.
18. Adimora NJ, Jones DP, Kemp ML. A model of redox kinetics implicates the thiol proteome in cellular hydrogen peroxide responses. Antioxid Redox Signal. 2010;13(6):731-743.
19. Kesarwani P, Murali AK, Al-Khami AA, Mehrotra S. Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal. 2013;18(12):1497-1534.
20. Malissen B, Grégoire C, Malissen M, Roncagalli R. Integrative biology of T cell activation. Nat Immunol. 2014;15(9):790-797.
21. Simeoni L, Bogeski I. Redox regulation of T-cell receptor signaling. Biol Chem. 2015;396(5):555-568.
22. Michalek RD, et al. The requirement of reversible cysteine sulfenic acid formation for T cell activation and function. J Immunol. 2007;179(10):6456-6467.
23. Chiu J, Dawes IW. Redox control of cell proliferation. Trends Cell Biol. 2012;22(11):592-601.
24. Vené R, et al. Redox remodeling allows and controls B-cell activation and differentiation. Antioxid Redox Signal. 2010;13(8):1145-1155.
25. Ueno H, Kajihara H, Nakamura H, Yodoi J, Nakamuro K. Contribution of thioredoxin reductase to T-cell mitogenesis and NF-kappaB DNA-binding promoted by selenite. Antioxid Redox Signal. 2007;9(1):115-121.
26. Chirullo B, et al. A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'anti-memory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis. 2013;4:e944.
27. Lewis MG, et al. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS. 2011;25(11):1347-1356.
28. Angelini G, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A. 2002;99(3):1491-1496.
29. Yan Z, Garg SK, Kipnis J, Banerjee R. Extracellular redox modulation by regulatory T cells. Nat Chem Biol. 2009;5(10):721-723.
30. Levring TB, et al. Activated human CD4+ T cells express transporters for both cysteine and cystine. Sci Rep. 2012;2:266.
31. Messina JP, Lawrence DA. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol. 1989;143(6):1974-1981.
32. Grek CL, Zhang J, Manevich Y, Townsend DM, Tew KD. Causes and consequences of cysteine S-glutathionylation. J Biol Chem. 2013;288(37):26497-26504.
33. Gould N, Doulias PT, Tenopoulou M, Raju K, Ischiropoulos H. Regulation of protein function and signaling by reversible cysteine S-nitrosylation. J Biol Chem. 2013;288(37):26473-26479.
34. Vint IA, Chain BM, Foreman JC. The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes. Cell Immunol. 1993;152(1):152-161.
35. Shytaj IL, et al. Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection. J Virol. 2015;89(15):7521-7535.
36. Lanna A, Henson SM, Escors D, Akbar AN. The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat Immunol. 2014;15(10):965-972.
37. Bogdan C. Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol. 2015;36(3):161-178.
38. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell. 1994;79(7):1137-1146.
39. Ibiza S, et al. Endothelial nitric oxide synthase regulates T cell receptor signaling at the immunological synapse. Immunity. 2006;24(6):753-765.
40. Ibiza S, et al. Endothelial nitric oxide synthase regulates N-Ras activation on the Golgi complex of antigen-stimulated T cells. Proc Natl Acad Sci U S A. 2008;105(30):10507-10512.
41. Benhar M, Forrester MT, Hess DT, Stamler JS. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science. 2008;320(5879):1050-1054.
42. Liu L, et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell. 2004;116(4):617-628.
43. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002;3(5):420-425.
44. Grek CL, Tew KD. Redox metabolism and malignancy. Curr Opin Pharmacol. 2010;10(4):362-368.
45. Parri M, Chiarugi P. Redox molecular machines involved in tumor progression. Antioxid Redox Signal. 2013;19(15):1828-1845.
46. Jorgenson TC, Zhong W, Oberley TD. Redox imbalance and biochemical changes in cancer. Cancer Res. 2013;73(20):6118-6123.
47. Castellani P, Balza E, Rubartelli A. Inflammation, DAMPs, tumor development, and progression: a vicious circle orchestrated by redox signaling. Antioxid Redox Signal. 2014;20(7):1086-1097.
48. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis. 2013;34(3):503-512.
49. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000;21(3):361-370.
50. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3(4):276-285.
51. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579-591.
52. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931-947.
53. Glasauer A, Chandel NS. Targeting antioxidants for cancer therapy. Biochem Pharmacol. 2014;92(1):90-101.
54. Albanes D, et al. α-Tocopherol and β-carotene supplements and lung cancer incidence in the α-tocopherol, β-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst. 1996;88(21):1560-1570.
55. Omenn GS, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150-1155.
56. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159(12):824-834.
57. Piskounova E, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;5 27(7577):186-191.
58. Harris IS, Brugge JS. Cancer: The enemy of my enemy is my friend. Nature. 2015;527(7577):170-171.
59. Yun J, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015;350(6266):1391-1396.
60. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003;23(3B):2425-2433.
61. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med. 2000;29(3-4):312-322.
62. Arnér ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006;16(6):419.
63. Vance TM, et al. Thioredoxin 1 in prostate tissue is associated with gleason score, erythrocyte antioxidant enzyme activity, and dietary antioxidants. Prostate Cancer. 2015;2015:728046.
64. Hellfritsch J, et al. Knockout of mitochondrial thioredoxin reductase stabilizes prolyl hydroxylase 2 and inhibits tumor growth and tumorderived angiogenesis. Antioxid Redox Signal. 2015;22(11):938-950.
65. Fiskus W, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014;74(9):2520-2532.
66. Celegato M, et al. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. Blood. 2015;126(11):1394-1397.
67. Kim IS, Jin JY, Lee IH, Park SJ. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol. 2004;142(4):749-755.
68. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal. 2011;15(4):1085-1127.
69. Patwardhan RS, Sharma D, Checker R, Thoh M, Sandur SK. Spatio-temporal changes in glutathione and thioredoxin redox couples during ionizing radiation-induced oxidative stress regulate tumor radio-resistance. Free Radic Res. 2015;49(10):1218-1232.
70. Fath MA, Ahmad IM, Smith CJ, Spence J, Spitz DR. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res. 2011;17(19):6206-6217.
71. Edes K, Cassidy P, Shami PJ, Moos PJ. JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1. PLoS One. 2010;5(1):e8786.
72. Cañas A, et al. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors. Breast Cancer Res. 2012;14(6):R153.
73. Saba NS, et al. Auranofin induces a reversible in-vivo stress response that correlates with a transient clinical effect in patients with chronic lymphocytic leukemia. Blood. 2013;122(21):3819.
74. Kast RE, Karpel-Massler G, Halatsch ME. CUSP9&z.ast; treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014;5(18):8052-8082.
75. Traverso N, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev. 2013;2013:972913.
76. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006;43(2):143-181.
77. Zhang W, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012;14(3):276-286.
78. Balendiran GK, Dabur R, Fraser D. The role of glutathione in cancer. Cell Biochem Funct. 2004;22(6):343-352.
79. DeNicola GM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):106-109.
80. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ, Hamilton TC. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 1995;55(19):4367-4374.
81. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22(47):7369-7375.
82. Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ. 2010;17(9):1373-1380.
83. Harris IS, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27(2):211-222.
84. Wu JH, Batist G. Glutathione and glutathione analogues; therapeutic potentials. Biochim Biophys Acta. 2013;1830(5):3350-3353.
85. O'Dwyer PJ, et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 1996;14(1):249-256.
86. Bailey HH, et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997;89(23):1789-1796.
87. Anderson CP, et al. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer. 2015;62(10):1739-1746.
88. Witte AB, Anestål K, Jerremalm E, Ehrsson H, Arnér ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005;39(5):696-703.
89. Kiebala M, et al. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol. 2015;43(2):89-99.
90. Zahedi Avval F, Holmgren A. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for Mammalian s phase ribonucleotide reductase. J Biol Chem. 2009;284(13):8233-8240.
91. Simons AL, Parsons AD, Foster KA, Orcutt KP, Fath MA, Spitz DR. Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells. J Oncol. 2009;2009:519563.
92. Sobhakumari A, et al. Susceptibility of human head and neck cancer cells tocombined inhibition of glutathione and thioredoxin metabolism. PLoS One. 2012;7(10):e48175.
93. Scarbrough PM, Mapuskar KA, Mattson DM, Gius D, Watson WH, Spitz DR. Simultaneous inhibition of glutathione- and thioredoxindependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med. 2012;52(2):436-443.
94. Sachweh MC, et al. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget. 2015;6(18):16488-16506.
95. You BR, Park WH. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion. Oncol Rep. 2015;35(1):546-551.
96. Shytaj IL, et al. Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology. 2013;10:71.
97. Staal FJ. Glutathione and HIV infection: reduced, or increased oxidized? Eur J Clin Invest. 1998;28(3):194-196.
98. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991;10(8):2247-2258.
99. Garaci E, et al. Intracellular GSH content and HIV replication in human macrophages. J Leukoc Biol. 1997;62(1):54-59.
100. Akerlund B, Jarstrand C, Lindeke B, Sönnerborg A, Akerblad AC, Rasool O. Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol. 1996;50(6):457-461.
101. Allard JP, et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIVinfected subjects. AIDS. 1998;12(13):1653-1659.
102. Kelly P, Musonda R, Kafwembe E, Kaetano L, Keane E, Farthing M. Micronutrient supplementation in the AIDS diarrhoea-wasting syndrome in Zambia: a randomized controlled trial. AIDS. 1999;13(4):495-500.
103. Narayan KM, et al. HIV and noncommunicable disease comorbidities in the era of antiretroviral therapy: a vital agenda for research in low- and middle-income country settings. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S2-S7.
104. Chomont N, DaFonseca S, Vandergeeten C, Ancuta P, Sékaly RP. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS. 2011;6(1):30-36.
105. Finzi D, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512-517.
106. Kazazi F, Koehler JK, Klebanoff SJ. Activation of the HIV long terminal repeat and viral production by H2O2-vanadate. Free Radic Biol Med. 1996;20(6):813-820.
107. Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci U S A. 1991;88(3):986-990.
108. Roederer M, Raju PA, Staal FJ, Herzenberg LA, Herzenberg LA. N-acetylcysteine inhibits latent HIV expression in chronically infected cells. AIDS Res Hum Retroviruses. 1991;7(6):563-567.
109. Piret B, Legrand-Poels S, Sappey C, Piette J. NF-κB transcription factor and human immunodeficiency virus type 1 (HIV-1) activation by methylene blue photosensitization. Eur J Biochem. 1995;228(2):447-455.
110. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood. 2009;113(1):58-65.
111. Shinozaki S, et al. Inflammatory stimuli induce inhibitory S-nitrosylation of the deacetylase SIRT1 to increase acetylation and activation of p53 and p65. Sci Signal. 2014;7(351):ra106.
112. Lusic M, Marini B, Ali H, Lucic B, Luzzati R, Giacca M. Proximity to PML nuclear bodies regulates HIV-1 latency in CD4+ T cells. Cell Host Microbe. 2013;13(6):665-677.
113. Mannick JB, et al. Nitric oxide modulates HIV-1 replication. J Acquir Immune Defic Syndr. 1999;22(1):1-9.
114. Khan SZ, Hand N, Zeichner SL. Apoptosisinduced activation of HIV-1 in latently infected cell lines. Retrovirology. 2015;12:42.
115. Kamio T, et al. B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. Blood. 2003;102(9):3317-3322.
116. Christopherson RI, Mactier S, Almazi JG, Kohnke PL, Best OG, Mulligan SP. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells. Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):375-383.
117. Tsai SY, Sun NK, Lu HP, Cheng ML, Chao CC. Involvement of reactive oxygen species in multidrug resistance of a vincristine-selected lymphoblastoma. Cancer Sci. 2007;98(8):1206-1214.
118. Savarino A, et al. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology. 2009;6:52.
119. Hütter G, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692-698.
120. Trono D, et al. HIV persistence and the prospect of long-term drug-free remissions forHIV-infected individuals. Science. 2010;329(5988):174-180.
121. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51-83.
122. Savarino A, Shytaj IL. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology. 2015;12:51.
123. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991-2001.
124. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26(9):1351-1356.
125. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem. 2005;12(11):1283-1294.
126. Niedbala W, Wei XQ, Piedrafita D, Xu D, Liew FY. Effects of nitric oxide on the induction and differentiation of Th1 cells. Eur J Immunol. 1999;29(8):2498-2505.
127. Lee SW, Choi H, Eun SY, Fukuyama S, Croft M. Nitric oxide modulates TGF-β-directive signals to suppress Foxp3+ regulatory T cell differentiation and potentiate Th1 development. J Immunol. 2011;186(12):6972-6980.
128. Friesen C, Kiess Y, Debatin KM. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ. 2004;11(suppl 1):S73-S85.
129. Conway JM, Perelson AS. Post-treatment control of HIV infection. Proc Natl Acad Sci U S A. 2015;112(17):5467-5472.
130. Shytaj IL, Savarino A. Cell-mediated anti-Gag immunity in pharmacologically induced functional cure of simian AIDS: a 'bottleneck effect'? J Med Primatol. 2015;44(5):227-240.
131. Deng K, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015;517(7534):381-385.
132. Patel M, Philip V, Fazel F. Human Immunodeficiency Virus Infection and Hodgkin's Lymphoma in South Africa: an emerging problem. Adv Hematol. 2011;2011:578163.
133. Davidson A, et al. Malignancies in South African children with HIV. J Pediatr Hematol Oncol. 2014;36(2):111-117.
134. Shytaj IL, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog. 2012;8(6):e1002774.
135. Apetrei C, Pandrea I, Mellors JW. Nonhuman primate models for HIV cure research. PLoS Pathog. 2012;8(8):e1002892.